晚发型糖原贮积病Ⅱ型临床、肌肉组织病理学及分子生物学特征分析

doi:10.3969/j.issn.1672-6731.2021.06.007

摘要/Abstract

摘要：

目的总结晚发型糖原贮积病Ⅱ型（GSDⅡ）的临床表现、肌肉组织病理学和分子生物学特征。方法与结果 选择2013年1月至2020年1月在郑州大学第五附属医院诊断与治疗的5例晚发型GSDⅡ型患者，临床主要表现为抬头无力、四肢近端肌无力、肌张力降低、不耐受疲劳和呼吸困难，酸性α葡糖苷酶（GAA）活性均明显降低。5例患者肌肉组织HE染色显示多数肌纤维内可见大小不一、数量不等、形态不规则的空泡样变性；改良Gomori三色染色可见空泡内有大量蓝紫色颗粒沉积；高碘酸-雪夫染色显示4例空泡内糖原成分增多，1例空泡内糖原成分流失。GAA基因检测显示，5例患者共检出9个变异位点，4例为复合杂合突变，分别来源于父亲和母亲，分别为c.1320_1322delGAT（p.Met440del）缺失突变、c.2331G > C（p.Thr777Thr）同义突变、c.2237G > A（p.Trp746*）无义突变、c.877G > A（p.Gly293Arg）错义突变、c.2238G > C（p.Trp746Cys）错义突变、c.784G > A（p.Glu262Lys）错义突变、c.2014C > T（p.Arg672Trp）错义突变和c.2332-2A > G剪切突变；1例为c.1432G > A（p.Gly478Arg）纯合突变，来源于母亲。其中，c.2331G > C、c.1432G > A和c.2332-2A > G系国内外首次报道。结论晚发型GSDⅡ型患者临床表现主要为四肢近端肌无力和呼吸困难，血清GAA酶活性明显下降，肌肉组织病理学具有特征性，GAA基因变异主要为复合杂合突变，其中，c.2331G > C、c.1432G > A和c.2332-2A > G为新发变异，扩展了GAA基因变异谱。

关键词: 糖原贮积病Ⅱ型, 晚发性障碍, &alpha, 葡糖苷酶类, 病理学, 分子生物学, 基因, 突变

Abstract:

Objective To summarize the clinical, muscle pathology and molecular biological features of late-onset glycogen storage disease type Ⅱ (GSDⅡ). Methods and Results Five patients with late-onset GSD Ⅱ diagnosed and treated in The Fifth Affiliated Hospital of Zhengzhou University from January 2013 to January 2020 were selected. The main clinical manifestations of 5 patients were weakness of raising the head, weakness of the proximal extremities, decreased muscle tone, fatigue intolerance, and dyspnea. The activity of acid α-glucosidase (GAA) was significantly reduced. HE staining of muscular tissues in 5 patients showed vacuole-like changes of different sizes, different numbers, and irregular shapes in most muscle fibers. Modified Gomori trichrome (MGT) staining showed a large number of blue and purple particles deposited in the vacuole. Periodic acid-Schiff (PAS) staining showed the glycogen content in the vacuoles were increased in 4 cases, and the glycogen content in the vacuoles were lost in one case. GAA gene testing showed that 9 mutations were detected in 5 patients, and 4 cases were compound heterozygous mutations, which were derived from father and mother respectively. The c.1320_1322delGAT (p.Met440del) was a deletion mutation, c.2331G > C (p.Thr777Thr) was a synonymous mutation, c.2237G > A (p.Trp746*) was a nonsense mutation, c.877G > A (p.Gly293Arg) was a missense mutation, c.2238G > C (p. Trp746Cys) was a missense mutation, c.784G > A (p.Glu262Lys) was a missense mutation, c.2014C > T (p. Arg672Trp) was a missense mutation, and c. 2332-2A > G was a splicing mutation. One case was homozygous mutation of c. 1432G > A (p. Gly478Arg), which originated from the mother. Among them, c. 2331G > C, c. 1432G > A and c. 2332-2A > G were reported for the first time at home and abroad. Conclusions The clinical manifestations of late-onset GSD Ⅱ are weakness of proximal limbs and dyspnea. The activity of GAA in peripheral serum is decreased significantly. Muscle tissue pathology is characteristic. GAA gene mutations are mainly compound heterozygous mutation, c.2331G > C, c.1432G > A and c.2332-2A > G are new mutations, which extended the mutation spectrum of GAA gene.

Key words: Glycogen storage disease type Ⅱ, Late onset disorders, alpha-Glucosidases, Pathology, Molecular biology, Genes, Mutation

吴世陶, 刘方, 石伟伟, 张敏, 刘恒方. 晚发型糖原贮积病Ⅱ型临床、肌肉组织病理学及分子生物学特征分析[J]. 中国现代神经疾病杂志, 2021, 21(6): 466-472.

WU Shi-tao, LIU Fang, SHI Wei-wei, ZHANG Min, LIU Heng-fang. Clinical, muscle pathology and molecular biological features of late-onset glycogen storage disease typeⅡ[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(6): 466-472.

http://journal11.magtechjournal.com/cjcnn/CN/Y2021/V21/I6/466

参考文献

[1] Alonso-Pérez J, Segovia S, Domínguez-González C, Olivé M, Mendoza Grimón MD, Fernández-Torrón R, López de Munain A, Muñoz-Blanco JL, Ramos-Fransi A, Almendrote M, Illa I, Díaz-Manera J. Spanish Pompe registry:baseline characteristics of first 49 patients with adult onset of Pompe disease[J]. Med Clin (Barc), 2020, 154:80-85.
[2] Ruggeri P, Lo Monaco L, Musumeci O, Tavilla G, Gaeta M, Caramori G, Toscano A. Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease[J]. Neurol Sci, 2020, 41:2175-2184.
[3] Neurology Society of Chinese Medical Association, Neuromuscular Group of Chinese Neurology Society, Electromyography and Clinical Neurophysiology Group of Chinese Neurology Society. Guidelines for the diagnosis and treatment of myopathic glycogen accumulation disease in China[J]. Zhonghua Shen Jing Ke Za Zhi, 2016, 49:8-16.[中华医学会神经病学分会, 中华医学会神经病学分会神经肌肉病学组,中华医学会神经病学分会肌电图与临床神经生理学组. 中国肌病型糖原累积病诊治指南[J]. 中华神经科杂志, 2016, 49:8-16.]
[4] Ngiwsara L, Wattanasirichaigoon D, Tim -Aroon T, Rojnueangnit K, Noojaroen S, Khongkraparn A, Sawangareetrakul P, Ketudat-Cairns JR, Charoenwattanasatien R, Champattanachai V, Kuptanon C, Pangkanon S, Svasti J. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand[J]. BMC Med Genet, 2019, 20:156.
[5] Martínez M, Romero MG, Guereta LG, Cabrera M, Regojo RM, Albajara L, Couce ML, Pipaon MS. Infantile-onset Pompe disease with neonatal debut:a case report and literature review[J]. Medicine (Baltimore), 2017, 96:e9186.
[6] Momosaki K, Kido J, Yoshida S, Sugawara K, Miyamoto T, Inoue T, Okumiya T, Matsumoto S, Endo F, Hirose S, Nakamura K. Newborn screening for Pompe disease in Japan:report and literature review of mutations in the GAA gene in Japanese and Asian patients[J]. J Hum Genet, 2019, 64:741-755.
[7] Stockton DW, Kishnani P, van der Ploeg A, Llerena J Jr, Boentert M, Roberts M, Byrne BJ, Araujo R, Maruti SS, Thibault N, Verhulst K, Berger KI. Respiratory function during enzyme replacement therapy in late-onset Pompe disease:longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start[J]. J Neurol, 2020, 267:3038-3053.
[8] Koeberl DD, Case LE, Desai A, Smith EC, Walters C, Han SO, Thurberg BL, Young SP, Bali D, Kishnani PS. Improved muscle function in a phase Ⅰ/Ⅱ clinical trial of albuterol in Pompe disease[J]. Mol Genet Metab, 2020, 129:67-72.
[9] Schneider I, Hensel O, Zierz S. Response:late-onset Pompe disease manifests in the brain[J]. Mol Genet Metab Rep, 2019, 21:100516.
[10] Schaaf GJ, van Gestel TJM, In't Groen SLM, de Jong B, Boomaars B, Tarallo A, Cardone M, Parenti G, van der Ploeg AT, Pijnappel WWMP. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease[J]. Acta Neuropathol Commun, 2018, 6:119.
[11] Korlimarla A, Spiridigliozzi GA, Crisp K, Herbert M, Chen S, Malinzak M, Stefanescu M, Austin SL, Cope H, Zimmerman K, Jones H, Provenzale JM, Kishnani PS. Novel approaches to quantify CNS involvement in children with Pompe disease[J]. Neurlogy, 2020, 95:e718-732.
[12] Fu Liong H, Abdul Wahab SA, Yakob Y, Lock Hock N, Thong WK, Viswanathan S. Late-onset glycogen storage disease type Ⅱ (Pompe's disease) with a novel mutation:a malaysian experience[J]. Case Rep Neurol Med, 2014:ID926510.
[13] Hahn A, Schänzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease[J]. Ann Transl Med, 2019, 7:283.
[14] Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease:a comprehensive overview[J]. Ann Transl Med, 2019, 7:278.
[15] Tarnopolsky MA, Nilsson MI. Nutrition and exercise in Pompe disease[J]. Ann Transl Med, 2019, 7:282.
[16] Bay LB, Denzler I, Durand C, Eiroa H, Frabasil J, Fainboim A, Maxit C, Schenone A, Spécola N. Infantile-onset Pompe disease:diagnosis and management[J]. Arch Argent Pediatr, 2019, 117:271-278.
[17] Salabarria SM, Nair J, Clement N, Smith BK, Raben N, Fuller DD, Byrne BJ, Corti M. Advancements in AAV-mediated gene therapy for Pompe disease[J]. J Neuromuscul Dis, 2020, 7:15-31.
[18] Al-Hassnan ZN, Khalifa OA, Bubshait DK, Tulbah S, Alkorashy M, Alzaidan H, Alowain M, Rahbeeni Z, Al-Sayed M. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients[J]. Mol Genet Metab Rep, 2018, 15:50-54.
[19] Zhang XT. Research advances in the diagnosis and treatment of Pompe disease[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2018, 20:588-593.[张昕彤. 庞贝病诊断与治疗的研究进展[J]. 中国当代儿科杂志, 2018, 20:588-593.]
[20] Nagura H, Hokugo J, Ueda K. Long-term observation of the safety and effectiveness of enzyme replacement therapy in Japanese patients with Pompe disease:results from the post-marketing surveillance[J]. Neurol Ther, 2019, 8:397-409.
[21] Bellotti AS, Andreoli L, Ronchi D, Bresolin N, Comi GP, Corti S. Molecular approaches for the treatment of Pompe disease[J]. Mol Neurobiol, 2020, 57:1259-1280.

选择文件类型/文献管理软件名称

选择包含的内容

2 晚发型糖原贮积病Ⅱ型临床、肌肉组织病理学及分子生物学特征分析

Clinical, muscle pathology and molecular biological features of late-onset glycogen storage disease typeⅡ

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任修德, 李涛, 范吉康, 王希森, 贾晓丹, 杨学军. 胶质母细胞瘤FGFR3-TACC3融合基因介导丙酮酸激酶M2入核促进DNA损伤修复基础研究[J]. 中国现代神经疾病杂志, 2023, 23(8): 745-757.
[2]	吴旭玲, 张安妮, 雷晓阳, 冯占辉, 王维, 贺电. 强直性肌营养不良症1型一例[J]. 中国现代神经疾病杂志, 2023, 23(8): 765-769.
[3]	马晓丽, 童家杰, 张秀智, 杜倩, 隋爱霞, 赵焕芬. 表现为垂体腺瘤卒中的黄色瘤性垂体炎[J]. 中国现代神经疾病杂志, 2023, 23(7): 599-603.
[4]	李跃文, 褚先舟, 李娟, 秦艳, 吴桐, 陈先文. BSCL2基因c.455A>G突变致远端型遗传性运动神经病V型一家系[J]. 中国现代神经疾病杂志, 2023, 23(7): 643-647.
[5]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[6]	崔立立, 纪坤乾, 张正华, 张同霞, 赵玉英. 以排尿困难发病的SOD1基因变异致肌萎缩侧索硬化一例[J]. 中国现代神经疾病杂志, 2023, 23(5): 472-476.
[7]	蔡洪钱, 张安妮, 徐子茜, 龚慧蓝, 曾红梅, 贺电. 伴PSEN2基因V214L突变的早发型阿尔茨海默病一家系临床研究[J]. 中国现代神经疾病杂志, 2023, 23(4): 335-340.
[8]	徐蓉, 宁泽淑, 康庆云, 陈波, 廖红梅, 杨理明, 吴丽文. 钾离子通道基因变异相关婴儿癫痫性脑病临床表型与基因变异特点分析[J]. 中国现代神经疾病杂志, 2023, 23(3): 196-204.
[9]	唐薇婷, 肖波. N-甲基-D-天冬氨酸受体GRIN2A基因变异与癫痫研究进展[J]. 中国现代神经疾病杂志, 2023, 23(2): 89-93.
[10]	李字林, 胡文瀚, 张凯. 癫痫外科常见病理类型体细胞突变研究进展[J]. 中国现代神经疾病杂志, 2023, 23(2): 115-123.
[11]	王圆圆, 王鲁宁, 朱明伟. 病理性TDP-43蛋白在常见神经系统变性疾病患者杏仁核中的表达变化[J]. 中国现代神经疾病杂志, 2022, 22(9): 787-794.
[12]	姚盈盈, 王雷明, 滕梁红. 脑胶质瘤DNA甲基化临床意义及研究进展[J]. 中国现代神经疾病杂志, 2022, 22(9): 823-828.
[13]	菅凤增, 王兴文. 分子病理诊断时代脊柱脊髓肿瘤的诊断与治疗[J]. 中国现代神经疾病杂志, 2022, 22(8): 651-654.
[14]	姚庆宇, 马龙冰, 菅凤增. 脊髓空洞症大鼠模型长期稳定性评价[J]. 中国现代神经疾病杂志, 2022, 22(8): 662-668.
[15]	夏钰, 沙倩倩, 朱雯华, 乔凯, 都爱莲. SCN4A基因R672G位点突变致低钾性周期性瘫痪伴肌萎缩一家系分析并文献复习[J]. 中国现代神经疾病杂志, 2022, 22(8): 717-722.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 晚发型糖原贮积病Ⅱ型临床、肌肉组织病理学及分子生物学特征分析

Clinical, muscle pathology and molecular biological features of late-onset glycogen storage disease typeⅡ

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价